Connecting the Brain and New Drug Targets for Schizophrenia

H. C. Whalley, J. D. Steele, P. Mukherjee, L. Romaniuk, A. M. McIntosh, J. Hall, S. M. Lawrie

    Research output: Contribution to journalReview articlepeer-review

    11 Citations (Scopus)

    Abstract

    One thing we know for certain after decades of functional imaging in schizophrenia is that it is not a disorder that can simply be attributed to circumscribed lesions in the brain. It is, in other words, a disorder of the connectivity of the brain. In this overview, we will consider the power of connectivity analyses of functional MRI ( and PET) data as tools for translational neuroscience. We describe the patterns of functional and effective disconnectivity seen in schizophrenia and particular psychotic symptoms, those that appear to be attributable to genetic and/or environmental risk factors for psychosis, the potential of these disconnectivities as trait and state biomarkers, and their sensitivity to drug effects. We conclude that substantial work needs to be done on standardising connectivity analyses across laboratories and that disconnectivity studies should be an integral part of drug discovery programmes.

    Original languageEnglish
    Pages (from-to)2615-2631
    Number of pages17
    JournalCurrent Pharmaceutical Design
    Volume15
    Issue number22
    Publication statusPublished - Aug 2009

    Keywords

    • Connectivity
    • fMRI
    • schizophrenia
    • INDEPENDENT COMPONENT ANALYSIS
    • DORSOLATERAL PREFRONTAL CORTEX
    • PARTIAL LEAST-SQUARES
    • ALTERED EFFECTIVE CONNECTIVITY
    • MAGNETIC-RESONANCE IMAGE
    • FUNCTIONAL CONNECTIVITY
    • GENETIC RISK
    • FMRI DATA
    • WORKING-MEMORY
    • FRONTOTEMPORAL CONNECTIVITY

    Cite this